https://news.medxy.ai/zh/optimizing-peep-in-ards/Medxy AIzh2026-04-03T16:09:05-07:00在无急性呼吸窘迫综合征 (ARDS) 患者中优化呼气末正压：从非劣效性到贝叶斯获益概率 https://news.medxy.ai/ja/non-ards-peep-optimization/Medxy AIja2026-04-03T16:07:43-07:00非 ARDS 患者の陽圧終末期陽圧（PEEP）最適化：非劣性からベイジアン利益確率へ https://news.medxy.ai/vi/optimal-end-expiratory-pressure/Medxy AIvi2026-04-03T16:05:39-07:00Tối ưu hóa Áp lực Cuối Hơi Thở Xuất Dương Trong Bệnh Nhân Không Có ARDS: Từ Không Thua Kém Đến Xác Suất Lợi Ích Bayesian https://news.medxy.ai/optimizing-peep-benefits/Medxy AIen2026-04-03T15:58:49-07:00Optimizing Positive End-Expiratory Pressure in Patients Without ARDS: From Non-Inferiority to Bayesian Probabilities of Benefit https://news.medxy.ai/zh/gender-differences-in-syncope-management/Medxy AIzh2026-04-03T13:52:37-07:00晕厥管理中的性别差异：临床试验和真实世界结果的证据 https://news.medxy.ai/ja/gender-imbalance-syncope-management/Medxy AIja2026-04-03T13:50:41-07:00性差による失神管理の不均衡：臨床試験と実世界アウトカムの証拠 https://news.medxy.ai/vi/gender-differences-syncope-management/Medxy AIvi2026-04-03T13:48:26-07:00Sự Khác Biệt Giới Tính trong Quản Lý Syncope: Bằng Chứng từ Thử Nghiệm Lâm Sàng và Kết Quả Thực Tế https://news.medxy.ai/sex-disparities-syncope-management/Medxy AIen2026-04-03T13:45:45-07:00Sex-Specific Disparities in Syncope Management: Evidence from Clinical Trials and Real-World Outcomes https://news.medxy.ai/zh/beyond-communication/Medxy AIzh2026-04-03T12:46:16-07:00超越沟通：语言障碍与痴呆症患者生命末期住院利用增加有关 https://news.medxy.ai/ja/beyond-communication-dementia-care/Medxy AIja2026-04-03T12:44:51-07:00コミュニケーションを超えて：認知症の終末期医療利用と言語障壁の関連 https://news.medxy.ai/vi/language-barriers-alzheimer-hospital-use/Medxy AIvi2026-04-03T12:41:36-07:00Ngoài giao tiếp: Rào cản ngôn ngữ liên quan đến việc sử dụng bệnh viện cao hơn vào cuối đời trong bệnh Alzheimer https://news.medxy.ai/language-barriers-hospital-utilization/Medxy AIen2026-04-03T12:37:52-07:00Beyond Communication: Language Barriers Linked to Higher Hospital Utilization at End-of-Life in Dementia https://news.medxy.ai/zh/severe-babesiosis-red-cell-exchange/Medxy AIzh2026-04-03T12:28:51-07:00严重巴贝斯病的红细胞交换输血：改善生存率和临床结局的证据 https://news.medxy.ai/ja/red-cell-exchange-transfusion-babesiosis/Medxy AIja2026-04-03T12:27:28-07:00重症巴贝斯虫病的红细胞交换输血：提高生存率和临床结果的证据 https://news.medxy.ai/vi/blood-transfusion-babesiosis/Medxy AIvi2026-04-03T12:25:07-07:00Truyền máu thay thế hồng cầu cho bệnh Babesiosis nặng: Bằng chứng về sự cải thiện tỷ lệ sống sót và kết quả lâm sàng https://news.medxy.ai/red-blood-cell-exchange-babesiosis/Medxy AIen2026-04-03T12:22:38-07:00Red Blood Cell Exchange Transfusion for Severe Babesiosis: Evidence for Improved Survival and Clinical Outcomes https://news.medxy.ai/zh/fluoxetine-covid-fatigue-results/Medxy AIzh2026-04-03T12:11:18-07:00氟西汀在治疗长期COVID疲劳方面显示前景：来自适应性随机试验的结果 https://news.medxy.ai/ja/fulbocare-hope-for-chronic-fatigue/Medxy AIja2026-04-03T12:10:14-07:00フルボキサミン、持続性コロナ疲労症候群の治療に有望：適応無作為化試験の結果 https://news.medxy.ai/vi/fluvoxamine-covid-fatigue/Medxy AIvi2026-04-03T12:08:21-07:00Fluvoxamine Hiển Thị Hứa Hẹn trong Điều Trị Mệt Mỏi Dài Hạn do COVID-19: Kết Quả từ Thử Nghiệm Ngẫu Nhiên Tự Động Điều Chỉnh https://news.medxy.ai/flussamine-long-covid-fatigue/Medxy AIen2026-04-03T12:04:42-07:00Fluvoxamine Shows Promise for Treating Long COVID Fatigue: Results from Adaptive Randomized Trial https://news.medxy.ai/zh/limited-success-gvhd-treatment/Medxy AIzh2026-04-03T11:46:30-07:00有限成功：三线治疗在糖皮质激素难治性伴胃肠道受累的急性移植物抗宿主病中的疗效 https://news.medxy.ai/ja/limited-success-gvhd-treatment/Medxy AIja2026-04-03T11:44:39-07:00限られた成功：ステロイド抵抗性の急性GVHD（消化器系関与）に対する第三選択療法が微弱な反応を示す https://news.medxy.ai/vi/limited-success-third-line-therapy-agvhd/Medxy AIvi2026-04-03T11:41:20-07:00Thành công hạn chế: Liệu pháp tuyến thứ ba cho aGvHD có liên quan đến đường tiêu hóa kháng corticosteroid đạt phản ứng khiêm tốn https://news.medxy.ai/limited-success-third-line-therapy-agvhd/Medxy AIen2026-04-03T11:38:15-07:00Limited Success: Third-Line Therapy Yields Modest Responses in Steroid-Refractory aGvHD with GI Involvement https://news.medxy.ai/zh/oncolytic-virus-multiple-myeloma/Medxy AIzh2026-04-03T11:18:43-07:00溶瘤牛疱疹病毒1型：多发性骨髓瘤免疫微环境重塑的新策略 https://news.medxy.ai/ja/reconstructing-microenvironment-multiple-myeloma/Medxy AIja2026-04-03T11:16:34-07:00多発性骨髄腫の免疫微小環境再構築における新型戦略：ボーバインヘルペスウイルス1型のオンコライティック効果 https://news.medxy.ai/vi/bovine-herpesvirus-oncology/Medxy AIvi2026-04-03T11:14:49-07:00Bovine Herpesvirus Type 1 Onco-lý: Chiến lược mới để tái cấu trúc vi môi trường miễn dịch trong bệnh đa u tủy https://news.medxy.ai/oncolytic-bhv1-myloema-remodeling/Medxy AIen2026-04-03T11:11:37-07:00Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma https://news.medxy.ai/zh/ribosome-collision-zak-toxicity/Medxy AIzh2026-04-03T10:56:46-07:00核糖体碰撞与ZAK依赖的核糖毒性应激反应：慢性髓系白血病的一种新型治疗脆弱性 https://news.medxy.ai/ja/ribosome-collision-cml-therapy/Medxy AIja2026-04-03T10:55:12-07:00リボソームの衝突とZAK依存性リボソーム毒性ストレス応答：慢性骨髄性白血病の新たな治療脆弱性 https://news.medxy.ai/vi/ribosome-stress-response-zak/Medxy AIvi2026-04-03T10:53:08-07:00Va chạm ribosome và đáp ứng căng thẳng ribotoxic phụ thuộc ZAK: Một điểm yếu điều trị mới trong bệnh bạch cầu mạn tính dòng tủy https://news.medxy.ai/ribosome-collisions-cml/Medxy AIen2026-04-03T10:49:47-07:00Ribosome Collisions and the ZAK-Dependent Ribotoxic Stress Response: A Novel Therapeutic Vulnerability in Chronic Myeloid Leukemia https://news.medxy.ai/zh/enterococcus-mhc-ii-mechanism/Medxy AIzh2026-04-03T09:05:53-07:00肠球菌粪肠亚种驱动肠道上皮表达MHC-II：一种将肠道微生物群失调与致命移植物抗宿主病联系起来的新机制 https://news.medxy.ai/ja/faecalis-mhc-ii-gvhd/Medxy AIja2026-04-03T09:04:35-07:00腸球菌faecalisが腸上皮におけるMHC-IIの発現を駆動する：腸内細菌叢の乱れと致死性GVHDの関連を解明する新規メカニズム https://news.medxy.ai/vi/enterococcus-faecalis-mhc-ii-gvhd/Medxy AIvi2026-04-03T09:02:49-07:00Enterococcus faecalis Kích Thích Biểu Hiện MHC-II trong niêm mạc ruột: Cơ Chế Mới Liên Kết Sự mất cân bằng vi sinh vật đường ruột với Bệnh Graft-versus-Host gây chết người https://news.medxy.ai/enterococcus-faecalis-mhc-ii-gvhd/Medxy AIen2026-04-03T08:58:27-07:00Enterococcus faecalis Drives MHC-II Expression in Intestinal Epithelium: A Novel Mechanism Linking Gut Microbiome Dysbiosis to Lethal Graft-versus-Host Disease